This phenomenon is largely due to selective dependency on anti-apoptotic proteins BCL-2, MCL-1, and BCL-xL following therapy, of which protein levels are comparable or increased between wild-type and mutant TP53 AML cells [20]. This evidence concerns the gene TP53 and acute myeloid leukemia.